Annals of Oncology 15:450-454, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB)
Received 16 June 2003; revised 13 October 2003; accepted 6 November 2003;Background:
Mammograms are assigned a BI-RADS (Breast Imaging Reporting and Data System) category, which indicates the level of suspicion for cancer.
Objectives:
(i) To evaluate the use of BI-RADS categories in a non-academic radiology practice based in a community hospital compared with local radiology private offices; (ii) to determine positive predictive value (PPV), sensitivity and specificity of mammograms; and (iii) to explore the correlation of BI-RAD 35 and lesion description with diagnosis of cancer.
Patients and methods:
We performed 947 SVABBs (stereotactic vacuum-assisted breast biopsies) on 911 patients with BI-RADS 35. Lesions were classified as: 1 = microcalcifications; 2 = asymmetric density; 3 = circumscribed mass; and 4 = spiculated mass.
Results:
BI-RADS category correlated with diagnosis of breast cancer (atypia excluded): category 3 = 4%; category 4 = 15%; and category 5 = 79%. The PPV of BI-RADS 4 and 5 for breast cancer or atypia was 20%, in contrast to 5% for BI-RADS 3. Sensitivity and specificity were 95% and 19%, respectively. For BI-RADS 3 without microcalcifications only 3% were positive, in contrast to 8% for remainder.
Conclusions:
First, there is a stepwise increase in cancer for each of the BI-RADS categories 35. Secondly, in BI-RADS 3 with microcalcifications, a biopsy is indicated according to our findings. Finally, the sensitivity of mammograms is 95% but the specificity is 19%.
Auxilio Mutuo Cancer, Hospital Auxilio Mutuo, San Juan, Puerto Rico
Key words: biopsy, BI-RADS category, cancer diagnosis, mammography, SVABB
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. Montserrat Treatment of Chronic Lymphocytic Leukemia: Achieving Minimal Residual Disease-Negative Status As a Goal J. Clin. Oncol., May 1, 2005; 23(13): 2884 - 2885. [Full Text] [PDF] |
||||
